Showing results (141-150 of 152) with videos related to
Sort By:
Pageof 16
Revue Medicale Suisse|June 22, 2006
[Therapeutic drug monitoring (TDM) of psychotropic drugs: a consensus guideline of the AGNP-TDM group]P Baumann, C Hiemke, S Ulrich, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|October 28, 2005
Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp)U Schmitt, A Abou El-Ela, L J Guo, et al.Pharmacopsychiatry|May 20, 2005
Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practiceK Grasmäder, P L Verwohlt, K-U Kühn, et al.Therapeutic Drug Monitoring|July 2, 2004
Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guidelineP Baumann, C Hiemke, S Ulrich, et al.Pharmacopsychiatry|November 20, 2004
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatryP Baumann, C Hiemke, S Ulrich, et al.Pharmacopsychiatry|November 17, 2011
The serotonin transporter promoter polymorphism (5-HTTLPR) affects the relation between antidepressant serum concentrations and effectiveness in major depressionN Dreimüller, A Tadić, A Dragicevic, et al.Psychopharmacology|October 19, 2023
Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysisX M Lense, C Hiemke, C S M Funk, et al.Pharmacopsychiatry|June 14, 2003
Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?M J Müller, A Dragicevic, M Fric, et al.Pharmacopsychiatry|November 5, 2011
AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011C Hiemke, P Baumann, N Bergemann, et al.Pharmacopsychiatry|October 5, 2011
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011C Hiemke, P Baumann, N Bergemann, et al.Pageof 16